Related Experiment Video

Updated: Jul 14, 2026

Implementation of Portable Emissions Measurement Systems (PEMS) for the Real-driving Emissions (RDE) Regulation in Europe
09:34

Implementation of Portable Emissions Measurement Systems (PEMS) for the Real-driving Emissions (RDE) Regulation in Europe

Published on: December 4, 2016

The European Regulation on medicines for paediatric use

Julia Dunne1

  • 1Medicines and Healthcare Products Regulatory Agency, 1 Nine Elms Lane, London SW8 9NQ UK. Julia.Dunne@mhra.gsi.gov.uk

Paediatric Respiratory Reviews
|June 19, 2007
PubMed

Insights

The European Paediatric Regulation mandates studying medicines in children and developing age-appropriate formulations. This encourages paediatric drug development and improves information availability, incentivized by patent extensions.

Area of Science:

  • Pharmaceutical Sciences
  • Regulatory Affairs
  • Pediatric Medicine

Background:

  • The European Regulation on medicines for paediatric use, effective January 26, 2007, significantly altered the landscape for pediatric drug development.
  • It aimed to enhance the availability of crucial information regarding medication use in children.

Purpose of the Study:

  • To outline the key provisions and anticipated impacts of the new European Paediatric Regulation.
  • To detail the mechanisms by which the regulation encourages the development of pediatric medicines and formulations.
  • To explain the incentives and infrastructure established to support pediatric drug research.

Main Methods:

  • Mandatory pediatric studies and age-appropriate formulation development for new medicines.
  • Incentives including patent term extensions and market exclusivity for companies conducting pediatric studies.
  • Establishment of a European pediatric clinical trials network and a study program for off-patent medicines.
  • Formation of a Paediatric Committee at the European Medicines Agency to oversee Paediatric Investigation Plans (PIPs).
  • Creation of a public-accessible European pediatric clinical trials database.

Main Results:

  • Companies are now required to investigate medicines in pediatric populations.
  • Age-appropriate formulations will be developed as a standard practice.
  • A framework for incentivizing pediatric drug research through intellectual property extensions is in place.
  • A dedicated committee and network will manage and execute pediatric clinical trials.
  • A database will centralize information on pediatric trial outcomes.

Conclusions:

  • The Paediatric Regulation represents a significant advancement in promoting pediatric drug development and ensuring safe, effective medication use in children.
  • The comprehensive approach, including mandatory studies, incentives, and dedicated infrastructure, is expected to improve pediatric medicine availability and information.
  • A review mechanism is incorporated to allow for future adjustments to the regulation based on its effectiveness.

Related Concept Videos

Pharmacokinetics in Pediatric Patients: Drug Excretion01:26

Pharmacokinetics in Pediatric Patients: Drug Excretion

In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...
Pharmacokinetics in Pediatric Patients: Drug Metabolism01:24

Pharmacokinetics in Pediatric Patients: Drug Metabolism

In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
Drug Regulation01:25

Drug Regulation

Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
Drug Dosing: Infants and Children01:29

Drug Dosing: Infants and Children

Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...